Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Business Wire
- BLA for veligrotug successfully submitted to the U.S. Food and Drug Administration (FDA) in late October following recent consultation with the agency -- Veligrotug’s Breakthrough Therapy Designation supports eligibility for potential Priority Review -- FDA decision whether to accept the BLA for filing is expected within 60 days of submission - WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successful October submission of its BLA to the U.S. Food and Drug Administration (FDA) for veligrotug, the company’s investigational therapy for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disorder characterized by inflammation and swelling of the tissues around the eyes, often leading to pain, vision impairment, and a significant reduction in quality of life.
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- VRDN's page on the SEC website